Get started
Author

Hillary Prescott

Observed names: Hillary A Prescott, Hillary Prescot, Prescott Hillary
OpenAlex ID: A5109414891
Thrombocytopenia in Patients With Myelodysplastic Syndromes
2010 · Jeffrey Bryan, Elias Jabbour, et al. · Seminars in Hematology · 39
Bosutinib for the treatment of chronic myeloid leukemia
2015 · Vi Doan, Alice Wang, et al. · American Journal of Health-System Pharmacy · 25
Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations
2019 · Michael J Reff, Alexandra Shillingburg, et al. · Journal of Oncology Pharmacy Practice · 12
Current and Future Management Options for Myelodysplastic Syndromes
2010 · Jeffrey Bryan, Elias Jabbour, et al. · Drugs · 12
Clofarabine in the treatment of myelodysplastic syndromes
2014 · Jeffrey Bryan, Hagop Kantarjian, et al. · Expert Opinion on Investigational Drugs · 10
Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
2013 · Elias Jabbour, Guillermo Garcia-Manero, et al. · Blood · 7
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
2011 · Hillary Prescott, Hagop Kantarjian, et al. · Expert Opinion on Emerging Drugs · 7
Clinical Use of Imatinib Plasma Levels in Patients with Chronic Myeloid Leukemia (CML)
2008 · Pat Ault, Hagop M. Kantarjian, et al. · Blood · 6
Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
2013 · Elias Jabbour, Hagop Kantarjian, et al. · Blood · 3
Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network
2023 · Jennifer P Booth, Julie M Kennerly-Shah, et al. · Journal of Oncology Pharmacy Practice · 2
Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
2013 · Elias Jabbour, Hagop M Kantarjian, et al. · Blood · 1
Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule
2018 · Elaine Xiang, Hillary Prescott, et al. · Blood
Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen
2018 · Patrick McBride, Houry Leblebjian, et al. · Blood
Treatment Options for Myelodysplastic Syndromes
2011 · Hillary Prescott, Elias Jabbour, et al. · European Oncology & Haematology
Treatment Options for Myelodysplastic Syndromes
2011 · Hillary Prescott, Elias Jabbour, et al. · touchREVIEWS in Oncology & Haematology
Works count: 15
Citation count: 124
H-index: 7
I10-index: 5
Year
Topic
Type